Valuation: Celsion Corporation

Market Cap 5.11M 4.57M 4.21M 3.81M 7.12M 485M 7.26M 50.17M 20.14M 255M 19.16M 18.76M 804M P/E 2026 *
-0.38x
P/E 2027 * -0.49x
Enterprise Value 5.11M 4.57M 4.21M 3.81M 7.12M 485M 7.26M 50.17M 20.14M 255M 19.16M 18.76M 804M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.18%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celsion Corporation

Manager TitleAgeSince
Chief Executive Officer 56 12/05/2024
Director of Finance/CFO 53 30/06/2026
Chief Tech/Sci/R&D Officer 73 17/02/2025
Director TitleAgeSince
Chairman 75 06/10/2014
Director/Board Member 75 07/07/2011
Director/Board Member 76 14/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
Average
Weighted average by Cap.

Financials

2026 *2027 *
Net sales - -
Net income -14.47M -12.96M -11.92M -10.8M -20.19M -1.37B -20.56M -142M -57.05M -723M -54.29M -53.14M -2.28B -18.55M -16.62M -15.28M -13.85M -25.89M -1.76B -26.37M -182M -73.16M -927M -69.62M -68.14M -2.92B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Celsion Corporation